ALLEGRA MEDICAL TECHNOLOGIES LIMITED SYDNEY 17 NOVEMBER, 2015 -Allegra Orthopaedics Limited (Allegra) (ASX: AMT), advises that it has appointed Sean Mulhearn as a director of Allegra.
Sean has been involved in the financial markets for over 30 years with experience in Asia, Europe, and the Americas. He holds a Bachelor of Economics from the University of Sydney and has obtained formal financial accreditations in the US and Asia.
Sean has particular expertise in risk management. He recently founded Jacaranda Capital Partners, a boutique advisory and markets training business with offices in Singapore and Australia.
Allegra's Executive Chairman, Peter Kazacos said, 'Allegra is pleased to have attracted someone of Sean's calibre as a director. He brings considerable experience to the Board'.
Contact Details:
Peter Kazacos - Executive Chairman Allegra Orthopaedics
T: 0413 624 171
Allegra Orthopaedics' focus is to deliver responsive customer service through our extensive capabilities. Our goal is to build a strong and profitable medical company.
Our principal product is the Active Total Knee, which has significantly improved the quality of life for people globally.
We also exclusively distribute Arthrosurface, Inc range of implantable orthopaedic devices.
Allegra Orthopaedics is the global licensee to a composite biocompatible ceramic material known as Sr-HT-Gahnite from The University of Sydney for veterinary and orthopaedic solutions. In preliminary studies, Sr-HT-Gahnite has duplicated the mechanical strength of bone and pre-clinical studies currently being performed indicate good bioactivity and ingrowth of bone into the synthetic scaffold prepared from this ceramic material.
Importantly, it is 100 times mechanically stronger than synthetic bone substitute materials in clinical use.
The company continues to build upon its extensive patent and product development portfolio. We have extensive research relationships with universities, companies and surgeon inventors. Our partnerships are building innovative products which will deliver significant shareholder wealth.
|
distributed by
|
